TEVA
Teva Pharmaceutical Industries Limited$32.91
LiveJun 16, 2026
Market cap
$38.32B
52w range
14.99 – 37.35
P / E
—
EPS
—
Volume
5.1M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Teva Pharmaceutical Industries Limited’s valuation06-05today
- Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?4d
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy6d
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy6d
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript8d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $39.29 (+19.39%)
Candlestick · 1Y
Open in chart workstation →TEVA
33.69-5.15%H 37.35L 27.93MA50 32.27MA200 —Avg vol 7.1M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.32% | -3.23% | -4.02% | +11.71% | +9.34% | +5.45% | +88.06% | +336.47% | +211.35% | -36.97% | +3531.45% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$33.00
1 sh
Bid
$32.75
1 sh
Ask
$33.05
100 sh
Spread
$0.300
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Energy+0.43%
- Basic Materials+0.29%
- Consumer Cyclical+0.27%
- Industrials+0.24%
- Consumer Defensive+0.12%
- Real Estate-0.33%
- Utilities-0.47%
- Financial Services-0.48%
- Healthcare-0.90%
- Communication Services-1.14%
- Technology-2.10%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - Specialty & Generic-1.00%
- Electronic Gaming & Multimedia+7.62%
- Communication Equipment-3.73%
- Hardware, Equipment & Parts-3.27%
- Independent Power Producers+2.90%
- Medical - Equipment & Services+2.81%
- Apparel - Manufacturers-2.54%
- Trucking-2.37%
- Internet Content & Information-2.28%
- Oil & Gas Drilling-2.16%
- Department Stores-2.15%
- Semiconductors-2.07%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?fool.com·Jun 12, 2026
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategyglobenewswire.com·Jun 10, 2026
- Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategyglobenewswire.com·Jun 10, 2026
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 08, 2026
- Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Careglobenewswire.com·Jun 08, 2026
- Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Careglobenewswire.com·Jun 08, 2026
- Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Choreaglobenewswire.com·Jun 05, 2026
- Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Choreaglobenewswire.com·Jun 05, 2026
Peers
No peer list available for TEVA.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|